Sanofi (NASDAQ:SNY – Free Report) – Investment analysts at Zacks Research lowered their Q3 2023 earnings estimates for shares of Sanofi in a research note issued on Thursday, October 5th. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $1.39 per share for the quarter, down from their prior estimate of $1.41. The consensus estimate for Sanofi’s current full-year earnings is $4.39 per share. Zacks Research also issued estimates for Sanofi’s Q4 2023 earnings at $0.89 EPS, Q1 2024 earnings at $1.09 EPS, Q3 2024 earnings at $1.53 EPS, Q4 2024 earnings at $1.09 EPS, Q1 2025 earnings at $1.42 EPS, Q3 2025 earnings at $1.47 EPS and FY2025 earnings at $5.39 EPS.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.07. Sanofi had a net margin of 16.07% and a return on equity of 27.94%. The firm had revenue of $10.85 billion during the quarter, compared to analyst estimates of $11.47 billion.
Get Our Latest Analysis on Sanofi
Sanofi Trading Down 0.3 %
NASDAQ SNY opened at $53.90 on Friday. The stock has a 50-day moving average of $53.44 and a 200-day moving average of $53.48. The company has a current ratio of 1.21, a quick ratio of 0.81 and a debt-to-equity ratio of 0.20. Sanofi has a 1-year low of $38.68 and a 1-year high of $57.82. The firm has a market cap of $136.32 billion, a PE ratio of 18.46, a price-to-earnings-growth ratio of 1.58 and a beta of 0.56.
Institutional Trading of Sanofi
Institutional investors have recently bought and sold shares of the company. Fairfield Bush & CO. bought a new position in Sanofi in the 1st quarter valued at approximately $26,000. Bank of New York Mellon Corp boosted its position in shares of Sanofi by 31.3% during the first quarter. Bank of New York Mellon Corp now owns 440,646 shares of the company’s stock valued at $22,623,000 after buying an additional 105,046 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Sanofi by 12.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 24,613 shares of the company’s stock worth $1,264,000 after buying an additional 2,805 shares in the last quarter. Yousif Capital Management LLC raised its position in Sanofi by 45.2% in the 1st quarter. Yousif Capital Management LLC now owns 42,041 shares of the company’s stock worth $2,158,000 after buying an additional 13,095 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Sanofi by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 300,009 shares of the company’s stock valued at $15,402,000 after acquiring an additional 1,391 shares during the period. 10.06% of the stock is owned by hedge funds and other institutional investors.
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
- Five stocks we like better than Sanofi
- How to Invest in Cybersecurity
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- Starbucks Is About To Become A Value Play You Can’t Miss
- When to Sell a Stock for Profit or Loss
- Intel to Unlock Value By Spinning Off Programmable Chip Unit
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
